Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Non-Current Deffered Revenue (2016 - 2025)

Iradimed (IRMD) has disclosed Non-Current Deffered Revenue for 13 consecutive years, with $4.0 million as the latest value for Q4 2025.

  • Quarterly Non-Current Deffered Revenue rose 32.91% to $4.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.0 million through Dec 2025, up 32.91% year-over-year, with the annual reading at $4.0 million for FY2025, 32.91% up from the prior year.
  • Non-Current Deffered Revenue for Q4 2025 was $4.0 million at Iradimed, up from $3.6 million in the prior quarter.
  • The five-year high for Non-Current Deffered Revenue was $4.0 million in Q4 2025, with the low at $1.4 million in Q4 2022.
  • Average Non-Current Deffered Revenue over 5 years is $2.6 million, with a median of $2.8 million recorded in 2024.
  • The sharpest move saw Non-Current Deffered Revenue dropped 29.82% in 2022, then soared 103.14% in 2023.
  • Over 5 years, Non-Current Deffered Revenue stood at $1.7 million in 2021, then decreased by 18.11% to $1.4 million in 2022, then skyrocketed by 103.14% to $2.8 million in 2023, then grew by 7.14% to $3.0 million in 2024, then skyrocketed by 32.91% to $4.0 million in 2025.
  • According to Business Quant data, Non-Current Deffered Revenue over the past three periods came in at $4.0 million, $3.6 million, and $3.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.